^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Marabex (MAGE-A3 vaccine)

    i
    Other names: MG1-MAGEA3, Ad MAGEA3, MG1 MA3, Ad-MG1-MAGEA3, MAGE-A3 vaccine, MG1MA3, MG1 Maraba/MAGE-A3
    Company:
    AbbVie, Turnstone Biologics
    Drug class:
    MAGE-A3 modulator
    Related drugs:
    3ms
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    10ms
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Dec 2023
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    over1year
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2022 --> Jun 2023
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK mutation
    |
    Marabex (MAGE-A3 vaccine)
    over3years
    Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (clinicaltrials.gov)
    P1/2, N=16, Completed, Turnstone Biologics, Corp. | Active, not recruiting --> Completed | N=75 --> 16 | Trial completion date: Aug 2021 --> May 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MAGEA3 (MAGE Family Member A3)
    |
    EGFR mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • Marabex (MAGE-A3 vaccine)